HRT After Ovarian Cancer: What the Guidelines Actually Say — and Why They Disagree About Your Subtype

HRT after ovarian cancer is not automatically ruled out. The answer turns on your exact histotype, stage, whether disease is present or recurrent, current endocrine treatment, and whether you need systemic or vaginal estrogen. High-grade serous disease is generally the most reassuring; low-grade serous, endometrioid, and granulosa-cell scenarios need stricter subtype-specific review.

The fact that changes the answer	What to find
Exact histotype	High-grade serous, low-grade serous, endometrioid, clear cell, mucinous, granulosa cell, germ cell, borderline, or another diagnosis
Current disease status	No evidence of disease, residual disease, active treatment, maintenance treatment, or recurrence
Treatment target	Whole-body symptoms that may require systemic treatment versus vaginal or urinary symptoms that may be approached locally

And there is one more thing that changes the answer: which specialist you ask. In a 2026 US survey, 49% of general OB-GYN attendings said they would prescribe estrogen therapy after epithelial ovarian cancer, compared with 78% of gynecologic-oncology attendings. The survey did not give every clinician the same detailed patient vignette, and it does not mean a specialist will automatically say yes. It does mean specialty materially changes the conversation.^[1]

So if you were told no without anyone naming the subtype-specific reason, there is a real case for reopening the question with the person who treats this disease every day.

First, put the disagreement in one table.

---

Is this page for you?

Answer capsule: This page is for women whose ovarian-cancer treatment caused menopause, whose symptoms are disrupting daily life, or who were given a blanket “no hormones after cancer” without a pathology-specific explanation. It is not a substitute for urgent evaluation, active-disease management, or a clinician reading your records.

This page is for you if	This page is not your right first stop if
Ovarian-cancer treatment pushed you into menopause and the symptoms are wrecking your life	You have new bloating, pelvic pain, feeling full quickly, or a change in bowel or bladder habits — contact your care team rather than trying to solve that symptom through an HRT article
You were told “no hormones after cancer” and nobody explained why	You are in treatment for active or recurrent disease and have not raised hormones with your oncology team
You do not know your tumour subtype and want to find it	You have never had ovarian cancer and are asking whether HRT could cause it — that is a different evidence question
You want the real numbers, including the parts that are weak	You want someone to promise that a treatment is safe for you. No honest web page can do that

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

Which ovarian cancer subtypes change the HRT answer?

Answer capsule: Ovarian cancer is a family of diseases, and hormone-therapy guidance splits by histotype, stage, residual disease, recurrence, and route. The US Society of Gynecologic Oncology and the UK’s joint cancer-and-menopause guideline agree in some rows, openly differ in others, and assess vaginal estrogen separately from systemic HRT.^[2][3]

This is The HRT Index Ovarian Cancer Subtype Ledger. We built it by comparing the SGO statement, the BGCS/BMS guideline, the 2026 histotype-specific cohort, and the evidence each document relies on. Where they conflict, we show the conflict instead of picking the answer that sounds easiest.

The UK guideline's general position—not a subtype-by-subtype trial result—is that vaginal estrogen is safe for the majority of women after gynecologic cancer, including many who cannot use systemic HRT, with rare exceptions. The vaginal-estrogen column therefore shows when the local-treatment question still needs separate specialist review rather than assigning each histotype its own proven safety grade.^[3]

Last verified August 2026.

Your subtype and disease status	US SGO / The Menopause Society (2020)	UK BGCS / British Menopause Society (2024)	2026 systemic-estrogen cohort	Vaginal estrogen in UK guidance	What this means in practice
High-grade serous	Acceptable	Not usually contraindicated; individual discussion	In the serous group, systemic estrogen use was associated with better survival: aHR 0.71 (95% CI 0.58–0.87). The authors interpreted the serous result as principally applicable to high-grade serous disease	Usually considered separately under the UK guideline's general vaginal-estrogen recommendation	The most reassuring epithelial scenario, but still not automatic clearance
Low-grade serous, Stage I	Not recommended at any stage	Nonhormonal options first, but systemic HRT is not contraindicated	Not reported separately from high-grade serous	Separate specialist decision; the systemic disagreement does not answer the local-treatment question	The US and UK guidance genuinely differ. This belongs with gynecologic oncology
Low-grade serous, Stage II–IV or recurrent	Not recommended	Not recommended because endocrine treatment can be useful in this disease	Not reported separately	Separate specialist decision	Systemic estrogen can conflict with an estrogen-suppressing treatment strategy; do not treat this as an online-care decision
Endometrioid, Stage I with no residual disease	Not recommended	Not contraindicated; nonhormonal options may be tried first	Systemic estrogen use was associated with worse survival: aHR 2.01 (95% CI 1.16–3.51); the result was not stage-specific	Separate specialist decision	The guideline split remains, but the 2026 observational signal raises the caution level
Endometrioid, Stage II+, residual, active, or recurrent	Not recommended	Use systemic HRT with caution because residual disease may be stimulated	Same concerning endometrioid association; not stage-specific	Separate specialist decision	This is not a routine systemic-HRT scenario
Clear cell	Not separately addressed	Systemic HRT can be considered after individual discussion	Associated with better survival: aHR 0.52 (95% CI 0.28–0.97)	Usually considered separately under the UK guideline's general vaginal-estrogen recommendation	Reassuring, but the cohort was observational and the confidence interval was wide
Mucinous	Not separately addressed	Systemic HRT can be considered after individual discussion	Evidence remained insufficient; the authors called for more research	Usually considered separately under the UK guideline's general vaginal-estrogen recommendation	More permissive guidance, thinner direct evidence
Granulosa cell, Stage I	Not addressed	Limited evidence has not demonstrated harm, but these tumours can be hormone-sensitive and uncertainty must be discussed	Not included in the epithelial-cancer cohort; a separate 2026 review found no direct evidence establishing safety or risk	Separate specialist decision	Specialist-only. “No demonstrated harm” is not proof of safety
Granulosa cell, Stage II+ or recurrent	Not addressed	Systemic HRT is not recommended in the summary table; nonhormonal treatment should be strongly considered first	Not included; a separate 2026 review found no direct evidence establishing safety or risk	Separate specialist decision	Generally avoid systemic estrogen unless a specialist team reaches an exceptional individualized decision
Germ-cell tumour with premature ovarian insufficiency	Not addressed	HRT should be offered when treatment caused ovarian failure, despite no direct post-cancer HRT studies	Not included	Usually considered separately under the UK guideline's general vaginal-estrogen recommendation	Often reasonable after exact pathology is confirmed; evidence is indirect
Borderline tumour, no residual disease	Insufficient evidence for a firm recommendation	HRT should be offered for symptoms and actively considered after early-stage treatment causing surgical menopause	Not included	Usually considered separately under the UK guideline's general vaginal-estrogen recommendation	The UK guidance is substantially more positive than the US statement
Borderline tumour with implants, microinvasion, residual, advanced, or recurrent disease	Insufficient evidence	Individual caution; do not apply the low-risk borderline recommendation to this group	Not included	Separate specialist decision	A different conversation from an early borderline tumour with no residual disease

Source: Sources for the ledger: SGO 2020; BGCS/BMS 2024; Lukey et al., Gynecologic Oncology, June 2026; Shore et al., Gynecologic Oncology Reports*, June 2026.^[2][3][4][5]

Two notes on how to read this.

“Not recommended” is not a loophole. It is not identical to a formal drug contraindication, but it still means the guideline advises against routine use. An exception would need a real specialist rationale, not a web page turning “not contraindicated” into permission.

The UK guideline splits several cancers by stage. The US statement usually does not. That explains part of the disagreement around low-grade serous and endometrioid disease. It does not explain all of it.

And the evidence changed in 2026. A peer-reviewed histotype-specific cohort included 2,334 people diagnosed with invasive epithelial ovarian cancer before age 60 who survived at least one year, including 446 post-diagnosis systemic-estrogen users. Its serous and clear-cell associations were reassuring; its endometrioid association was not.^[4]

That study is observational. It can show an association after statistical adjustment; it cannot prove that estrogen caused a better or worse outcome. It also lacked tumour-stage data, excluded people who did not survive the first year, and studied systemic estrogen rather than vaginal estrogen. It is too relevant to leave out and too limited to turn into a causal verdict.^[4]

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult. For this page specifically, that safety flag is already triggered: ovarian-cancer history is a specialist-first situation. Find My HRT Path is an education-and-routing tool, not pathology interpretation or oncology clearance. Online care is not the right starting point until someone qualified has reviewed the cancer-specific question.

---

What did The HRT Index actually verify?

Answer capsule: We checked the full SGO and BGCS/BMS guidance, the randomized-trial and Cochrane results, the 2026 histotype cohort’s publication record and abstract, the current US prescribing survey, and current FDA labels for the nonhormonal drugs discussed below. We did not interpret a reader’s pathology, choose a product or dose, or claim clinician review.

We verified in August 2026:

• The SGO clinical practice statement, including its ovarian-cancer recommendation table.^[2]
• The BGCS/BMS 2024 guideline, including the ovarian histotype text, systemic-versus-vaginal summary table, timing guidance, bone-health recommendations, nonhormonal options, and compounded-product position.^[3]
• The AHT randomized trial and the National Cancer Institute’s summary of its design and limitations.^[6]
• The Cochrane review estimates and certainty ratings.^[7]
• The 2023 systematic review and meta-analysis.^[8]
• The June 2026 histotype-specific cohort by Lukey and colleagues.^[4]
• The 2026 US clinician survey on estrogen prescribing after gynecologic cancer.^[1]
• The current FDA labeling for Brisdelle, Veozah, and Lynkuet, including the August 2026 Lynkuet warning update.^[9][10][11]
• FDA’s current position separating FDA-approved hormone therapy from compounded preparations.^[12][13]
• DEA’s current classification of testosterone as a Schedule III controlled substance.^[14]

We did not paraphrase subscription-gated NCCN Survivorship wording we could not inspect. We also did not verify any individual provider’s willingness to manage ovarian-cancer survivorship, so this page does not promise that an online service will review a pathology report or accept a specific case.

What we did not do matters as much as what we did. We did not read your pathology, recommend a medicine, set a dose, calculate recurrence risk, or have this page reviewed by a clinician.

---

Is HRT safe after ovarian cancer? Here are the actual numbers

Answer capsule: The randomized and pooled evidence in epithelial ovarian cancer has not shown a general survival or recurrence penalty from post-diagnosis hormone therapy. The largest randomized trial enrolled 150 women and reported better overall and relapse-free survival with estrogen, while Cochrane judged the pooled evidence low certainty. A 2026 observational cohort added reassuring serous and clear-cell results—and a concerning endometrioid signal.^[6][7][4]

“Reassuring” is not enough. The number and its limit need to sit in the same row. Here they are.

Quick definition: a hazard ratio compares the rate at which an event occurs over follow-up. A hazard ratio below 1.00 means the event rate was lower in the treatment group during the study; it is not a promise that an individual’s risk falls by the same percentage. If a 95% confidence interval crosses 1.00, the result is not statistically significant at the conventional 0.05 level.

What was found	Estimate	Study and population	What it can answer	What it cannot answer
Better overall survival with estrogen	HR 0.63 (95% CI 0.44–0.90)	AHT randomized trial; 150 women; median follow-up 19.1 years	Mixed-histology randomized evidence does not support a universal survival penalty	The trial was small, unblinded, stopped early for slow recruitment, and began in an older treatment era
Better relapse-free survival	HR 0.67 (95% CI 0.47–0.97)	Same AHT trial	No general recurrence penalty appeared in the randomized population	It was not powered to settle each histotype separately
Possible overall-survival benefit	HR 0.71 (95% CI 0.54–0.93)	Cochrane 2020; 3 studies; 350 women	The pooled direction is reassuring	Cochrane rated the certainty low
Little or no clear progression-free-survival effect	HR 0.76 (95% CI 0.57–1.01)	Cochrane 2020; 2 studies; 275 women	No statistically clear harm signal	The interval crosses 1.00 and certainty was low
Better pooled overall and progression-free survival	HR 0.66 and HR 0.73	2023 meta-analysis; 8 publications; 3,578 patients; 912 HRT users	A larger synthesis strengthens the overall reassuring direction	Most included evidence was not randomized and remains vulnerable to selection bias
Better survival association in serous disease	aHR 0.71 (95% CI 0.58–0.87)	2026 population cohort; 2,334 patients diagnosed before 60 who survived at least one year; 446 systemic-estrogen users	Adds modern histotype-specific evidence, mainly relevant to high-grade serous disease	No tumour-stage data; one-year-survivor cohort; no vaginal-estrogen analysis; association is not causation
Better survival association in clear-cell disease	aHR 0.52 (95% CI 0.28–0.97)	Same 2026 cohort	Reassuring signal in a separately reported histotype	Smaller subgroup, wide interval, and no tumour-stage data
Worse survival association in endometrioid disease	aHR 2.01 (95% CI 1.16–3.51)	Same 2026 cohort	A real reason for heightened caution and specialist review	Observational, not stage-specific, limited to one-year survivors, and not proof of causation

Cochrane’s own conclusion was that the evidence was “too limited to support or refute that HRT is very harmful.”^[7]

That is not “it is safe.” It is not “it is dangerous.” It is an accurate description of why two reasonable doctors can give different answers—and why a subtype-specific study can change one row without changing all the others.

Here is what the total evidence does rule out: the old blanket statement that estrogen after every epithelial ovarian cancer inevitably causes recurrence. The mixed-histology randomized data did not show that.

Here is what it does not rule out: subtype-specific risk, risk during active or residual disease, conflict with estrogen-suppressing treatment, or uncertainty in rare tumours that have barely been studied.

Does that sound like your situation—treatment is behind you, the symptoms are real, and nobody has walked you through the reasoning?

Check which care route should come first with Find My HRT Path →

The live tool takes about 90 seconds, requires no email, and is for education and routing only. Use it to organize later online-care options—not to bypass the specialist-first step on this page. It cannot interpret your pathology or clear HRT after cancer.^[15]

---

Does taking estrogen make ovarian cancer come back?

Answer capsule: In mixed epithelial-ovarian-cancer trials, estrogen users did not have higher recurrence, and the largest randomized trial reported better relapse-free survival. That does not make every histotype equivalent: low-grade serous and granulosa-cell cancers can be hormone-responsive, and the 2026 cohort gives endometrioid disease a separate reason for caution.^[6][3][4]

The fear behind this question is that estrogen “feeds” the cancer. For some ovarian cancers, that concern is biologically and clinically real. For others, receptor staining alone does not predict the same response.

The BGCS/BMS guideline reports that estrogen receptors are found in up to 85% of high-grade serous and endometrioid ovarian cancers. If receptor presence alone decided the question, high-grade serous disease would be an automatic no. It is not: SGO calls hormone therapy acceptable in high-grade serous disease.^[2][3]

Why? Because having a receptor is not the same as proven clinical hormone dependence. High-grade serous disease may express estrogen receptors without responding to endocrine treatment the way low-grade serous disease does.

Low-grade serous is different. Endocrine treatment—including aromatase inhibitors—is used because lowering estrogen can control disease in selected settings. If you are actively taking an aromatase inhibitor, adding systemic estrogen is not a neutral move; it conflicts with the treatment strategy.

Endometrioid disease is now harder to dismiss with a receptor-only argument. The UK guidance remains more permissive after Stage I disease, but the 2026 cohort found a worse-survival association among systemic-estrogen users with endometrioid ovarian cancer. That result does not prove causation. It does mean a generic “ER status does not matter” answer is no longer good enough.^[3][4]

So the real question is not merely “Is my tumour ER positive?” It is “What is my exact histotype, is disease present, and is estrogen suppression part of my treatment strategy?”

A single “ER positive,” “weakly positive,” or “ER negative” line is not a verdict. Subtype, stage, residual disease, recurrence, and current treatment sit above it.

---

Which ovarian cancer subtypes are hormone-sensitive?

Answer capsule: Low-grade serous ovarian carcinoma is the clearest hormone-responsive epithelial subtype because endocrine drugs are used in its treatment. Granulosa-cell tumours can produce estrogen and may recur late. High-grade serous, clear-cell, and mucinous cancers are not generally managed as estrogen-driven in the same way, while endometrioid disease remains the disputed row.^[2][3]

High-grade serous—the most common epithelial subtype, and the most reassuring

This is where the evidence is strongest. SGO calls hormone therapy acceptable. The UK guideline says it is not usually contraindicated. The randomized evidence and the 2026 serous cohort point in the same reassuring direction.^[2][3][6][4]

If this is your subtype and you were told a flat no without a second reason—active disease, a clot history, liver disease, unexplained bleeding, another cancer, or a treatment conflict—that is the conversation worth reopening.

Low-grade serous—the clearest systemic-HRT conflict

For Stage II–IV or recurrent disease, the US and UK guidance point the same way. Endocrine drugs such as letrozole and anastrozole lower estrogen on purpose. Systemic estrogen can work against that strategy.^[2][3]

For Stage I disease, the guidelines split. SGO says not recommended. BGCS/BMS says try nonhormonal options first but does not call systemic HRT contraindicated. That gap is a specialist conversation, not a web-page permission slip.

Endometrioid—the row that changed in 2026

SGO: not recommended. BGCS/BMS: not contraindicated after Stage I disease, but use caution in advanced or residual disease.^[2][3]

The damaging detail is that the older randomized AHT trial included endometrioid cases—about 10% of its population—but did not publish a powered endometrioid-specific outcome. For years, that left the negative US recommendation resting largely on biological reasoning while the mixed-histology trial looked reassuring overall.

The 2026 cohort added the missing histotype-specific signal, and it was not reassuring: systemic-estrogen use in endometrioid ovarian cancer was associated with worse survival, aHR 2.01. The study was observational and not stage-specific, so it does not close the argument. It does close the door on treating Stage I endometrioid disease as an easy yes.^[4]

We are not saying the UK guideline is wrong or that an adjusted association has settled causation. We are saying this is now the row where a generic online answer is least defensible.

Clear cell and mucinous

The UK guideline says systemic HRT can be considered in both after individual discussion because endocrine treatment is not routinely used in the same way as it is for low-grade serous disease.^[3]

The 2026 clear-cell result was reassuring: aHR 0.52. The confidence interval was wide, so “reasonable to discuss” remains the right conclusion—not “proven safe.” Mucinous disease still lacks a comparable answer; the 2026 authors specifically called for more research.^[4]

Granulosa-cell and other sex-cord stromal tumours

Granulosa-cell tumours can produce estrogen. That is why caution runs through the guidance.

The UK guideline says the limited Stage I evidence has not demonstrated harm but also says the evidence base is minimal. A separate 2026 narrative review found no direct evidence establishing either safety or risk and documented that most recommendations still caution against menopausal hormone therapy because these tumours are hormonally active. In more advanced or recurrent disease, nonhormonal treatment should be strongly considered first, and the UK summary table classifies systemic HRT as not recommended.^[3][5]

One number deserves its own line because it changes what “five years clear” means. In a registry review cited by the UK guideline, 33% of recurrences occurred within five years, 50% between five and nine years, and 17% more than ten years after diagnosis. A reported recurrence occurred 37 years later.^[3]

That does not mean recurrence is inevitable. It means the usual five-year psychological finish line is a poor substitute for tumour-specific follow-up.

Germ-cell tumours

The UK guideline says HRT should be offered when treatment caused premature ovarian insufficiency. It is equally direct about the evidence gap: no specific post-cancer HRT studies exist for this rare group, so the recommendation rests on the expected lack of hormone responsiveness and the noncancer consequences of losing ovarian function young.^[3]

Borderline ovarian tumours

This is where the UK guideline is most positive. It recommends offering HRT for menopausal symptoms after a borderline tumour and actively considering it after early-stage treatment that caused surgical menopause, provided no residual or recurrent disease changes the picture.^[3]

The Swedish observational data behind that discussion included 150 women with borderline tumours. After five years, 93% were alive and 51% had used HRT after diagnosis. There were three ovarian-cancer deaths, and none occurred among HRT users. That is reassuring observational detail, not randomized proof.^[3]

SGO calls the evidence insufficient. Not a no. Not a yes. A gap.

---

How do you find out which subtype you had?

Answer capsule: Your histotype is usually recorded on the surgical pathology report under “Final Diagnosis” or in a synoptic summary. It is not the same as tumour grade or FIGO stage, and it may be missing from discharge paperwork. In the US, HIPAA generally gives you the right to request a copy of your medical record, including pathology.^[16]

Everything above depends on one word. Many women reading this page do not know that word, and it is not their fault—it may never have been said out loud.

Three things get confused constantly. They are not the same:

• Subtype or histotype — what kind of tumour it is: high-grade serous, low-grade serous, endometrioid, clear cell, mucinous, granulosa cell, germ cell, or another diagnosis. This is the field that drives the hormone-specific evidence.
• Grade — how abnormal the cells look. “Grade 1” is not the same as “low-grade serous.” A Grade 1 endometrioid tumour and a low-grade serous tumour are different diagnoses with different guidance.
• Stage — how far the cancer had spread, generally described using FIGO Stage I through IV.

Where to look: “Final Diagnosis,” “Microscopic Description,” or a “Synoptic Report” box. You want the surgical pathology report—not only the operative report, which describes the surgery, and not only the discharge summary, which may compress the diagnosis.

Copy this records request:

“I am requesting a copy of my complete surgical pathology report from my operation on [date] for my records. Please include the final diagnosis, synoptic report, histotype, grade, FIGO stage, receptor testing, and any amended or outside-review report.”

In the US, the records department may verify your identity and apply the access procedures permitted under HIPAA. You do not need a medical reason beyond wanting your own records.^[16]

Before the appointment, write these six fields on one page:

1. Exact histotype.
2. Tumour grade.
3. FIGO stage.
4. Whether residual disease remained after surgery.
5. Current status: no evidence of disease, active disease, or recurrence.
6. Every current cancer treatment, including maintenance and endocrine therapy.

That page is more useful than asking a generic clinic, “Can I take HRT after cancer?”

---

Is vaginal estrogen different from systemic HRT after ovarian cancer?

Answer capsule: Yes. Systemic HRT is intended to affect the whole body, while low-dose vaginal estrogen treats local vaginal and urinary symptoms and is assessed separately in the UK gynecologic-cancer guideline. A no to systemic HRT is not automatically a no to vaginal estrogen, but local treatment still needs to be matched to the tumour, current treatment, and proposed product.^[3]

If systemic HRT is off the table for your subtype, do not stop reading here. This may be the section that changes your options.

Systemic HRT includes patches, gels, sprays, and tablets intended to treat whole-body symptoms such as hot flashes and night sweats. It can also affect bone loss. The route changes some noncancer risks, but changing a tablet to a patch does not erase a cancer-specific contraindication.

Vaginal estrogen is applied locally as a cream, tablet, insert, or ring to treat genitourinary syndrome of menopause—vaginal dryness, irritation, painful sex, and some urinary symptoms.

The BGCS/BMS guideline gives the most memorable comparison on this page:

With current low-dose preparations, the total amount of vaginal estrogen used across a year is roughly comparable to a single oral systemic dose.^[3]

A year versus one systemic dose.

That is why the UK guideline treats vaginal estrogen more permissively and says it is suitable for the majority of women after gynecologic cancer, including many for whom systemic HRT is not appropriate. Its grade for that statement is B, stronger than many of the subtype-specific systemic recommendations in the same document.^[3]

Two honest limits belong next to that sentence. Low systemic absorption is not zero absorption. And “safe for the majority” does not mean “self-start without reviewing the rare exception, active treatment, or tumour context.”

The same guideline says vaginal estrogen can be started after the vagina has healed from surgery when it is otherwise appropriate, and it does not impose an arbitrary maximum duration. That is not a universal number of days after an operation; healing and treatment status have to be assessed.^[3]

Nonhormonal options are real and underused:

• A vaginal moisturizer used regularly—not only during sex.
• A lubricant used during sexual activity.
• Pelvic-floor physical therapy after pelvic surgery or radiotherapy.
• Evaluation for infection, scarring, narrowing, pelvic-floor spasm, or another cause when pain persists.

These may be enough for some women. They are not automatically equivalent to vaginal estrogen when symptoms remain severe.

If you also have a personal breast-cancer history, say it before discussing vaginal estrogen, vaginal DHEA, or ospemifene. That second cancer history can change the local-treatment conversation.^[3]

---

Can you start HRT during chemotherapy or maintenance treatment?

Answer capsule: There is no universal rule that every woman must finish all cancer treatment before HRT can be discussed. The UK guideline allows HRT during chemotherapy or radiotherapy in selected women without a contraindication, but current disease, final histology, endocrine treatment, clot risk, and the exact maintenance drug can change the answer. No consumer table can clear a specific drug combination.^[3]

Maintenance therapy creates a question a generic yes-or-no answer cannot resolve.

If you are on…	What can be said with confidence	The question to ask
Aromatase inhibitor such as letrozole or anastrozole	The drug lowers estrogen on purpose. Adding systemic estrogen can directly conflict with that treatment strategy	“Is systemic estrogen incompatible with the reason I am taking this drug, and what nonhormonal or local options remain?”
PARP inhibitor such as olaparib or niraparib	No direct ovarian-cancer evidence establishes a blanket yes or no for adding systemic HRT during PARP maintenance. The complete medication and supplement list needs an interaction review. The UK guideline specifically discourages St John’s wort because of interactions with chemotherapy and PARP inhibitors	“Does my maintenance drug change the timing, route, monitoring, or supplements I should avoid?”
Bevacizumab	There is no direct HRT-plus-bevacizumab evidence that turns this into a simple green light. Bevacizumab itself carries arterial- and venous-thromboembolism warnings, while cancer, surgery, mobility, and personal history add to the total risk	“What is my total clot risk, and would a transdermal route change the noncancer part of that risk?”[17]
Chemotherapy or radiotherapy	UK guidance permits HRT during treatment in selected women when there is no contraindication	“Has final histology and staging made this a straightforward case, or should the decision wait?”
No current treatment or maintenance	There is still no automatic yes. Histotype, residual or recurrent disease, general contraindications, and symptom target remain the gate	“Is there a cancer-specific reason to wait, or can we decide now?”

Transdermal estrogen—patch or gel—is associated with lower venous-thromboembolism risk than oral estrogen in general menopause guidance. That can matter when clot risk is already part of the picture. It does not make a hormone-sensitive tumour suitable for systemic HRT.^[3]

There is no universal five-year rule. The SGO and BGCS/BMS guidance do not tell every survivor to wait two years, five years, or another fixed anniversary. When the tumour is not hormone-sensitive and no other contraindication exists, treatment may be considered as soon as clinically appropriate. When the case is complex, the UK guideline says to wait for final histology, completed staging, and the treatment plan.^[3]

There is no universal two-year stop rule either. The UK guideline says arbitrary limits should not be placed on duration when treatment remains appropriate. Duration still needs review as age, symptoms, cancer status, and general health change.^[3]

---

Am I definitely in menopause after ovarian-cancer treatment?

Answer capsule: If both ovaries were removed, the menopause is immediate and permanent. If an ovary remains after fertility-sparing surgery or chemotherapy, absent periods do not always prove permanent loss of ovarian function. HRT is not contraception, so pregnancy prevention remains a separate question when ovarian function could return.^[18]

If both ovaries were removed, this section is simple: ovarian hormone production stopped on the day of surgery.

If you had one ovary removed, retained ovarian tissue, or had chemotherapy with ovaries in place, the answer is less clean. Ovarian function may be reduced, interrupted, or permanently lost; treatment type, dose, age, and time since treatment matter.

Two practical consequences follow:

1. Do not use a period-free interval caused by treatment as your only proof that pregnancy is impossible.
2. Do not treat HRT as birth control. FSRH guidance states that HRT is not a contraceptive method when menopausal status is uncertain.^[18]

That does not mean every survivor needs contraception. It means the question should be answered deliberately rather than inferred from symptoms or one blood test.

---

What does going without hormone therapy after ovarian cancer cost?

Answer capsule: Premature loss of ovarian hormones can affect bone, cardiovascular, sexual, urinary, and cognitive health across decades, especially when treatment causes menopause far earlier than the usual age. That does not override a hormone-sensitive cancer. It means the decision is between two sets of risks—not between risk and perfect safety.^[3]

This is the side of the ledger that gets left out when someone says no in a sentence.

The BGCS/BMS guideline lists the consequences of treatment-induced premature ovarian insufficiency plainly: bone loss and fracture risk, cardiovascular consequences, sexual and urinary symptoms, fertility loss, and possible neurocognitive effects. Pelvic radiotherapy can add another bone insult.^[3]

And it says something that should be printed on a card and handed to every survivor: a gynecologic malignancy is not automatically a contraindication to HRT.^[3]

Its bone-health recommendations are concrete whether or not HRT is used:

• Consider baseline bone-density testing with DEXA—or FRAX plus DEXA where appropriate—for premenopausal women with treatment-induced menopause and women starting an aromatase inhibitor.
• Consider a baseline vitamin D level or vitamin D supplementation for women at higher risk of bone loss.
• Encourage weight-bearing exercise, smoking cessation, reduced alcohol intake, and adequate dietary calcium.
• For women under 50, use HRT to prevent bone loss when it is not contraindicated.

Those are assessment points, not a fixed supplement prescription from this page. Kidney disease, kidney stones, absorption disorders, diet, current blood levels, and other medicines can change what “adequate” means.

Hold both sides at once. Recurrence fear is legitimate. So are years of untreated consequences. Neither side automatically wins, and anyone who tells you it does—in either direction—is skipping the hard part.

---

Should an online HRT provider be your first stop after ovarian cancer?

Answer capsule: Usually not. The HRT Index compares online menopause providers and may earn commission when readers start care with some of them, but this decision turns on pathology, current disease status, and oncology treatment. Do not assume a generic intake includes oncology-record review or coordination; get the cancer-specific question resolved first.

Let’s be straightforward about how this site works.

We earn money when readers start care with some telehealth providers we review. On many pages, sending the right reader toward a verified provider is reasonable.

On this page, it is not the first move.

A questionnaire can collect a cancer history. That is not the same as a gynecologic oncologist reviewing the pathology, deciding whether the tumour is hormone-responsive, and reconciling the decision with active treatment.

Do not assume an online service will obtain or interpret oncology records. Ask directly:

• Will a licensed clinician review my complete pathology report before systemic HRT is considered?
• Will the clinician coordinate with my gynecologic oncologist?
• Can the service manage a cancer-survivorship case, or will it refer me out?
• Does the service offer nonhormonal and local options when systemic HRT is not appropriate?
• Will I receive an FDA-approved product or a compounded preparation?

If the answer is vague, the service is the wrong first door.

The prescriber gap is real—but use the current number correctly

A 2026 US survey asked 270 clinicians whether they would prescribe estrogen therapy after epithelial ovarian cancer. Overall, 65.2% said yes. Among attending physicians, 49% of general OB-GYNs said yes, compared with 78% of gynecologic oncologists.^[1]

This was not an identical-case experiment, and the 78% figure was not permission for every histotype. Among clinicians who did prescribe, high-grade serous was by far the most commonly selected histology.

An earlier Swedish vignette study found an even wider gap—63.7% of general gynecologists versus 92% of gynecologic oncologists for the same ovarian-cancer scenario. That is useful historical evidence of specialty variation, not a current US prescribing rate.^[19]

The point survives the correction: who answers the question can materially change the answer.

If you were told no and never told which pathology, disease-status, or general contraindication drove it, the useful next step is not a faster prescription. It is a better question in the right room.

Does that fit what happened to you?

Use Find My HRT Path to check whether your route should begin with a specialist →

The tool does not clear ovarian-cancer survivors for hormones. On this page, specialist review belongs first; the tool is for organizing possible online-care routes later.

---

What if HRT is not an option after ovarian cancer?

Answer capsule: A no to systemic HRT is not a sentence to untreated symptoms. Three nonhormonal prescription drugs are FDA-approved specifically for moderate-to-severe menopausal vasomotor symptoms, and additional nonhormonal options have supporting evidence. The right choice still depends on current cancer drugs, liver status, seizure history, other medicines, and the symptom being treated.^{[9][10][11][20]}

If your subtype is low-grade serous, advanced or recurrent granulosa-cell, or an endometrioid scenario where systemic estrogen is being avoided, this is not a consolation paragraph. It is the treatment-plan section.

The honest framing from the BGCS/BMS guideline is that nonhormonal therapies can reduce menopausal symptoms, but none is generally as effective as estrogen for vasomotor symptoms. “Not as effective as the most effective treatment” is a long way from “nothing.”^[3]

The three FDA-approved nonhormonal medicines for hot flashes

Medicine	FDA status	The material detail that cannot be left out
Brisdelle (paroxetine) 7.5 mg	FDA-approved for moderate-to-severe vasomotor symptoms associated with menopause	It is an SSRI with a boxed warning about suicidal thoughts and behaviors in young people. Paroxetine is a strong CYP2D6 inhibitor, and the label says it may reduce tamoxifen effectiveness. The approved VMS dose is 7.5 mg, not 10 mg[9]
Veozah (fezolinetant)	FDA-approved in May 2023 for moderate-to-severe vasomotor symptoms	FDA added a boxed warning for rare but serious liver injury. Liver tests are required before treatment, monthly for the first three months, and again at months 6 and 9[10]
Lynkuet (elinzanetant)	FDA-approved in October 2025 for moderate-to-severe vasomotor symptoms	The current August 2026 label requires baseline liver testing and repeat testing at three months; it also warns about daytime impairment, pregnancy loss, drug interactions, and seizure risk[11]

As of August 2026, the US has three FDA-approved nonhormonal prescription drugs specifically for moderate-to-severe menopausal vasomotor symptoms. Current Lynkuet labeling makes liver testing and seizure risk part of the decision.^[9][10][11]

Established off-label and behavioral options

The Menopause Society’s 2023 position statement recommends several evidence-based nonhormonal approaches, including:

• Cognitive behavioral therapy.
• Clinical hypnosis.
• Selected SSRIs and SNRIs.
• Gabapentin.
• Oxybutynin.
• Fezolinetant, which was the approved neurokinin option at the time of that statement.^[20]

Venlafaxine is often discussed when an SNRI is appropriate. Paroxetine and fluoxetine can interfere with tamoxifen metabolism, so a personal breast-cancer history or current tamoxifen use changes the antidepressant choice.^[9][3] Gabapentin can be useful when night symptoms and sleep disruption travel together, but sedation matters. Oxybutynin can reduce hot flashes in some women, but dry mouth, constipation, urinary retention, and longer-term anticholinergic cognitive concerns matter—especially with age or other anticholinergic medicines.^[3][20]

The Menopause Society’s 2023 evidence statement does not recommend pregabalin for vasomotor symptoms, so it is not presented as a standard option here.^[20]

A whole-package approach can make more sense than handing someone one pill. The 2024 Menopause After Cancer study tested a multimodal program combining medication, digital CBT, and lifestyle support in women with treatment-induced menopause after cancer and reported improved cancer-related quality of life.^[21]

What to avoid treating as a workaround

• Phytoestrogen supplements are not a clean way around a hormone-sensitive-tumour restriction.
• St John’s wort can interact with cancer medicines, including chemotherapy and PARP inhibitors.
• Black cohosh and other supplements are not automatically safer because they are sold without a prescription.
• Exercise is valuable for bone, heart, mood, and function, but it should not be sold as a reliably equivalent hot-flash treatment.^[3][20]

Can testosterone replace estrogen after ovarian cancer?

No. Testosterone is not a general workaround for an estrogen restriction, because some testosterone is converted to estrogen in the body. The UK guideline says it should not be used when estrogen is contraindicated and limits evidence-based menopause use to hypoactive sexual desire disorder after other causes have been considered.^[3]

In the United States, testosterone is a Schedule III controlled substance and requires a prescription. No FDA-approved testosterone product is approved for women. Any use in a woman is off-label and still requires a clinician to assess the indication, product, dose, monitoring, and cancer context.^[14][22]

There is not enough evidence to recommend testosterone for brain fog, fatigue, or general energy. It is not “estrogen without the estrogen problem.”

---

Are FDA-approved and compounded hormones the same after ovarian cancer?

Answer capsule: No. FDA-approved hormone products are evaluated before marketing for safety, effectiveness, manufacturing quality, and labeling. Compounded preparations are not FDA-approved and do not go through that premarket review. No compounded product should be presented as safer, more natural, clinically equivalent, or interchangeable with an FDA-approved finished product.^[12]

Some online providers offer compounded hormone preparations made by a compounding pharmacy. That is a different regulatory category from an FDA-approved finished medicine.

Question	FDA-approved finished product	Compounded preparation
FDA premarket review for safety and effectiveness	Yes	No
FDA-approved labeling for the finished product	Yes	No
Manufacturing oversight	Subject to the applicable FDA-approved product and manufacturing framework	Governed by compounding laws and pharmacy requirements, not the same premarket approval process
Can it be called safer, more natural, or equivalent?	No medicine is risk-free	No. Those claims are not supported
When is it normally discussed?	When an approved option fits the need	When a prescriber identifies a patient-specific medical need an FDA-approved drug cannot meet[13]

FDA says it has no evidence that compounded “bioidentical” hormones are safer or more effective than FDA-approved hormone therapy. FDA also says there are no FDA-approved estriol drugs. Its compounding guidance says compounded drugs should be used only when a patient’s needs cannot be met by an FDA-approved drug.^[12][13]

The BGCS/BMS guideline independently recommends against compounded bioidentical hormone therapy because of concerns about purity, safety, and efficacy.^[3]

For a woman with a cancer history, the practical problem is evidence matching. The guideline and trial discussions on this page assume defined products and dosing. A compounded preparation cannot be silently treated as though it inherited the evidence for an FDA-approved finished product.

If online care becomes appropriate after the cancer-specific decision is made, ask one question before paying: “Is the product FDA-approved, or is it compounded?” Any provider should answer directly.

---

Which type of HRT gets discussed after ovarian cancer?

Answer capsule: Whether hormone therapy is appropriate comes first. Only then do route and regimen get selected. Uterus status, endometriosis history, clot risk, symptom target, age, other contraindications, and whether treatment is systemic or local determine whether clinicians discuss estrogen alone, estrogen plus a progestogen, a patch or gel, an oral product, or vaginal estrogen.^[3][12]

If your uterus was removed: estrogen-only systemic treatment is often the regimen discussed. A history of endometriosis can change that. The UK guideline recommends continuous combined HRT after surgical menopause in some women with endometriosis because unopposed estrogen may stimulate remaining endometriotic tissue.^[3]

If you still have your uterus: systemic estrogen generally needs adequate progestogen to protect the endometrium. That requirement comes from uterine protection, not from the ovarian-cancer diagnosis itself.^[12]

Patch or gel versus tablet: transdermal estrogen is associated with lower clot risk than oral estrogen in general menopause guidance. It can solve a route-related risk issue. It cannot solve a tumour-related contraindication.^[3] For the broader noncancer tradeoffs by route, see HRT benefits and risks.

On dose: use the lowest effective dose that meets the treatment target, with extra caution where tumour stimulation remains a concern. This page does not publish or recommend a dose.^[3]

On blood tests: the UK guideline says serum estrogen levels should not routinely be used to titrate HRT other than when absorption is in question. Symptom response, side effects, the regimen, and the clinical context matter more than chasing an online “optimal” number.^[3]

---

Is HRT after ovarian cancer the same question as whether HRT causes ovarian cancer?

Answer capsule: No. Incidence studies ask whether hormone therapy changes the chance that a person without ovarian cancer will develop it. Survivorship studies ask whether treatment after diagnosis changes recurrence, progression, or survival. Combining those two evidence streams produces a misleading answer.

Evidence question	Who the research starts with	What it measures	The source set that belongs here
Could HRT contribute to developing ovarian cancer?	People without ovarian cancer	New ovarian-cancer diagnoses	Incidence cohorts and prevention-risk research
What happens when HRT is used after ovarian cancer?	People already diagnosed and treated	Recurrence, progression, and survival	Post-diagnosis trials, survivor cohorts, and cancer-specific guidance

You will find statistics about HRT and the chance of developing ovarian cancer. Those studies start with women who do not have the disease.

That is not the question on this page. This page asks what happens after diagnosis and treatment, and it relies on post-diagnosis trials, cohorts, and cancer-specific guidelines.

The two bodies of evidence can look different without contradicting each other because they involve different populations, different outcomes, and different biological questions. A small incidence association cannot be pasted into a recurrence discussion as though it answers the same thing.

If you have never had ovarian cancer, do not use this page as your risk calculator. If you have had it, do not let an incidence statistic replace a pathology-specific survivorship discussion.

---

Who should you ask about HRT after ovarian cancer?

Answer capsule: Start with a gynecologic oncologist when histotype, residual disease, recurrence, or cancer treatment could change the answer. A menopause-trained clinician experienced in cancer survivorship can then help turn that cancer decision into a symptom, route, monitoring, and follow-up plan. A general online intake should not be the only gate.

The UK guideline lists several reasons for specialist-menopause referral, including premature ovarian insufficiency, contraindications to HRT, multiple treatment failures, poor symptom control, complex medical history, and past hormone-dependent cancer.^[3]

Being told you cannot have HRT is therefore not a reason for the conversation to end. It can be the reason to move the conversation to a clinician who handles complex menopause care.

Bring these records

1. Complete surgical pathology report.
2. Exact histotype, grade, and FIGO stage.
3. Operative report and whether residual disease remained.
4. Current disease status.
5. Chemotherapy, radiotherapy, maintenance, and endocrine-treatment history.
6. Current medication and supplement list.
7. Whether your uterus and either ovary remain.
8. Endometriosis history.
9. Personal history of clot, stroke, heart attack, liver disease, unexplained bleeding, breast cancer, or uterine cancer.
10. Your top two symptom priorities.

That final item matters. It turns a vague fight over “HRT” into a conversation about a specific target: hot flashes, sleep, vaginal pain, urinary symptoms, sexual function, or bone protection.

Ask these questions

1. What exact histotype is written on my final pathology report?
2. What was my FIGO stage, and was any disease left after surgery?
3. Am I currently considered to have no evidence of disease, active disease, or recurrent disease?
4. Is my subtype treated as hormone-responsive?
5. Were ER or PR results reported, and how much weight should they carry compared with histotype?
6. Are US and UK guidance consistent for my exact situation, or do they disagree?
7. Does the 2026 endometrioid, serous, or clear-cell cohort apply to me—and what are its limits?
8. Am I taking an aromatase inhibitor or another treatment that would conflict with systemic estrogen?
9. Are my main symptoms systemic, vaginal or urinary, or both?
10. Could vaginal estrogen be considered separately if systemic HRT is not right for me?
11. If systemic treatment is reasonable, would a patch or gel change my clot risk compared with a tablet?
12. Does my endometriosis history change the regimen even after hysterectomy?
13. Which nonhormonal options fit my symptoms and current cancer medicines?
14. Should I have a bone-density assessment?
15. When could treatment start, and what finding would make you stop or reconsider it?
16. Who coordinates follow-up—oncology, gynecology, primary care, or a menopause specialist?

Micro-commitment: copy the six pathology fields and these questions into your phone now. The next appointment gets better before it begins.

---

How was this page built?

Answer capsule: This page was built from primary guideline documents, peer-reviewed studies, current FDA labeling, and official regulatory sources—not from provider marketing copy. Where authorities disagree, the disagreement is visible. Where evidence is observational or low certainty, the design and limitation sit beside the number.

This is The HRT Index Verification Standard applied to a clinical evidence page:

1. Clinical legitimacy — use cancer-specific guidelines, primary studies, and current regulatory sources.
2. Care quality — identify when pathology review, oncology coordination, and specialist follow-up are necessary.
3. Medication fit — separate systemic from vaginal treatment and FDA-approved from compounded products.
4. Price transparency — do not publish a price or “starting at” claim that has not been verified. This page contains no provider price because price is not the deciding fact here.
5. Access — show where online care may fit later and where it is the wrong first starting point.

We do not publish a numeric score for this page or invent one for any clinician or provider.

Why there is no survivor testimonial here

A quote from one woman saying estrogen worked out fine would function as a safety claim it cannot support. It could tilt a cancer decision using someone else’s outcome.

So there is no testimonial pretending to prove recurrence safety, no first-person experience we do not have, and no “real woman” story selected because it converts.

The human truth still belongs here: when the conversation feels closed, some women act alone. Reopening it is safer than pretending the question is settled.

---

Frequently asked questions about HRT after ovarian cancer

Answer capsule: These short answers preserve the same conditions as the full article: histotype, stage, residual or recurrent disease, current treatment, symptom target, and route. They can close a follow-up question, but they cannot replace pathology review or individual prescribing.

Can you take HRT if you have had ovarian cancer?

Often, yes—but not from the diagnosis alone. High-grade serous disease has the most reassuring guidance and evidence. Low-grade serous, endometrioid, granulosa-cell, residual, recurrent, and active-disease scenarios require stricter review.^[2][3][4]

Is HRT safe after high-grade serous ovarian cancer?

SGO calls hormone therapy acceptable for high-grade serous disease. The UK guideline is also broadly permissive after individual discussion, and the 2026 serous cohort reported a reassuring survival association. None of that turns a web page into individual clearance.^[2][3][4]

Can you take HRT after low-grade serous ovarian cancer?

Stage and treatment status matter. SGO advises against systemic HRT across low-grade serous disease. BGCS/BMS is more permissive after Stage I but advises against systemic HRT in Stage II–IV or recurrent disease, where estrogen-suppressing treatment can be useful.^[2][3]

Can you take HRT after endometrioid ovarian cancer?

This is the most disputed epithelial row. US guidance advises against it; UK guidance is more permissive after Stage I disease. The 2026 cohort found a worse-survival association among systemic-estrogen users with endometrioid disease, so this needs heightened specialist caution rather than a generic yes.^[2][3][4]

Can you take HRT after clear-cell ovarian cancer?

UK guidance says systemic HRT can be considered after individual discussion. Among people diagnosed before age 60 who survived at least one year, the 2026 cohort reported a reassuring association, aHR 0.52, but the result was observational, lacked tumour-stage data, and had a wide interval.^[3][4]

Can you take HRT after a granulosa-cell tumour?

This is a specialist-only decision. Stage I evidence is extremely limited; advanced or recurrent disease is more concerning because granulosa-cell tumours can be hormone-responsive and recur late. The UK summary table does not recommend systemic HRT after Stage II or higher disease. A separate 2026 review found no direct evidence establishing safety or risk and documented continued caution because these tumours can be hormonally active.^[3][5]

Can you take HRT after a borderline ovarian tumour?

The UK guideline recommends offering HRT for symptoms after borderline tumours and is especially supportive after early-stage treatment causing surgical menopause when there is no residual disease. Implants, microinvasion, residual disease, advanced disease, or recurrence require a different discussion.^[3]

Does estrogen make ovarian cancer come back?

The mixed-histology randomized trials did not show a general recurrence penalty, and the largest reported better relapse-free survival. That does not settle hormone-responsive subtypes or the concerning endometrioid association in the 2026 observational cohort.^[6][7][4]

Does an ER-positive result mean I cannot take HRT?

Not by itself. Many high-grade serous cancers express estrogen receptors, yet SGO still considers hormone therapy acceptable in that histotype. Histotype, stage, residual disease, recurrence, and current endocrine treatment carry more weight than one receptor line.^[2][3]

Is vaginal estrogen safe after ovarian cancer?

The UK guideline assesses it separately and says it is suitable for the majority of women after gynecologic cancer, including many who cannot use systemic HRT. Low absorption is not zero, and active disease, current treatment, personal breast-cancer history, and the exact product still matter.^[3]

Do you have to wait five years before starting HRT?

No universal five-year rule appears in the US or UK guidance. Straightforward cases may be discussed as soon as clinically appropriate; complex cases should wait for final histology, staging, and the treatment plan.^[3]

Can HRT start during chemotherapy?

UK guidance says HRT can be started during chemotherapy or radiotherapy in selected women when there is no contraindication. That is an oncology-led option, not a self-directed rule.^[3]

Can I take HRT while on a PARP inhibitor?

The sources reviewed for this page do not establish a blanket yes or no for every PARP-maintenance case. The cancer, disease status, full medication list, and interactions need review. St John’s wort should be avoided because of interaction concerns with chemotherapy and PARP inhibitors.^[3]

If I had a hysterectomy, do I still need progesterone?

Estrogen-only systemic HRT is often discussed after hysterectomy. A history of endometriosis can change that; the UK guideline recommends continuous combined HRT in some women after surgical menopause to reduce stimulation of remaining endometriotic tissue.^[3]

How long can I stay on HRT?

The UK guideline says arbitrary duration limits should not be imposed when treatment remains appropriate. Continued use still needs periodic review of symptoms, cancer status, age, and general health.^[3]

Can testosterone be used instead if estrogen is not an option?

Not as a workaround. Testosterone can be converted to estrogen, has insufficient evidence for brain fog or fatigue, and in the US is a Schedule III controlled substance requiring a prescription. No FDA-approved testosterone product is approved for women.^[3][14][22]

Are compounded bioidentical hormones safer after ovarian cancer?

No. Compounded preparations are not FDA-approved, and FDA has no evidence that compounded “bioidentical” hormones are safer or more effective than FDA-approved hormone therapy. They must remain clearly separated from approved finished products.^[12]

What are the alternatives if systemic HRT is not an option?

FDA-approved nonhormonal options for moderate-to-severe hot flashes include Brisdelle, Veozah, and Lynkuet. Selected SSRIs or SNRIs, gabapentin, oxybutynin, CBT, and clinical hypnosis may also be discussed. The current cancer-drug list and each medicine’s warnings still control the choice.^{[9][10][11][20]}

Does a BRCA1 or BRCA2 mutation change the answer after ovarian cancer?

A mutation does not replace the post-cancer analysis. Evidence about HRT after preventive ovary removal in a BRCA carrier who never had ovarian cancer is a different population from someone treated for ovarian cancer. Your histotype, stage, disease status, current treatment, and any personal breast-cancer history still control the discussion.^[2][3]

Does this guidance also apply after fallopian-tube or primary peritoneal cancer?

The UK guideline groups ovarian, fallopian-tube, and primary peritoneal cancers in its overall framework. Exact histology and current disease status still drive the individual decision.^[3]

Why did one doctor say no when the guideline says HRT may be acceptable?

There may be a real reason: histotype, residual disease, recurrence, endocrine treatment, clot history, liver disease, unexplained bleeding, or another cancer. Prescribing also varies by specialty. Ask which specific fact drove the answer rather than assuming the doctor was either careless or automatically right.^[1]

---

Still not sure which HRT care route is right for you?

Answer capsule: Ovarian-cancer history is not a normal provider-matching case. Use the free routing tool to identify when specialist review must come first, then compare care routes only after the cancer-specific decision has been made.

Find My HRT Path →

It takes about 90 seconds, requires no email, and organizes online-care routes from your symptoms, care preference, safety history, and state. For ovarian-cancer history, use it only after accepting this page’s specialist-first handoff. It does not diagnose, interpret pathology, calculate recurrence risk, or replace a licensed clinician.^[15]

---

You survived the part nobody prepares you for. Wanting to feel well on the other side of it is not ingratitude, and it is not reckless.

It is a fair question with a real answer. And that answer starts with one word printed on a piece of paper you are entitled to request.

Last verified: August 2026 · Editorial standards · Corrections policy · How we make money

---

Sources

¹ McDowell JL, Strawderman M, Betstadt SJ, Moore RG. “Estrogen therapy in patients with gynecologic cancer: a survey of gynecologists and oncologists in the United States.” Menopause. 2026;33(2). doi:10.1097/GME.0000000000002643. The Menopause Society manuscript PDF: https://menopause.org/wp-content/uploads/press-release/MENO-D-25-00238.pdf

² Sinno AK, Pinkerton J, Febbraro T, et al. “Hormone therapy in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology clinical practice statement.” Gynecologic Oncology. 2020;157(2):303–306. Official statement PDF: https://esgo.org/media/2023/07/Sinno-2020-HRT-gyn-cancer-clinical-practice-statement.pdf

³ British Gynaecological Cancer Society and British Menopause Society. Management of Menopausal Symptoms Following Treatment of Gynaecological Cancer. August 2024. https://www.bgcs.org.uk/wp-content/uploads/2024/08/BGCS-BMS-Guidelines-on-Management-of-Menopausal-Symptoms-after-Gynaecological-Cancer.pdf

⁴ Lukey A, Salmanpour A, Kaur P, et al. “Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis.” Gynecologic Oncology. 2026;209:69–74. doi:10.1016/j.ygyno.2026.04.018. PubMed record: https://pubmed.ncbi.nlm.nih.gov/42102524/ · Institutional publication record: https://scholars.duke.edu/publication/1821354

⁵ Shore A, Fang L, Hewins S, et al. “Granulosa cell tumors and menopausal hormone therapy: A narrative review.” Gynecologic Oncology Reports. 2026;65:102123. https://pmc.ncbi.nlm.nih.gov/articles/PMC13254716/

⁶ Eeles RA, Morden JP, Gore M, et al. “Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the AHT randomized trial.” Journal of Clinical Oncology. 2015;33(35):4138–4144. National Cancer Institute summary: https://www.cancer.gov/types/ovarian/research/hrt-survival

⁷ Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. “Hormone replacement therapy after surgery for epithelial ovarian cancer.” Cochrane Database of Systematic Reviews. 2020;1:CD012559. https://www.cochrane.org/evidence/CD012559_hormone-replacement-therapy-after-surgery-epithelial-ovarian-cancer

⁸ Achimaș-Cadariu PA, Păun DL, Pașca A. “Impact of hormone replacement therapy on overall survival and progression-free survival of ovarian cancer patients: A systematic review and meta-analysis.” Cancers. 2023;15(2):356. https://doi.org/10.3390/cancers15020356

⁹ US Food and Drug Administration. Brisdelle (paroxetine) prescribing information, revised February 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204516s009s014lbl.pdf

¹⁰ US Food and Drug Administration. “FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant).” Updated December 2024. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due

¹¹ US Food and Drug Administration. Drug Trials Snapshot: Lynkuet (FDA approval dated 24 October 2025), and DailyMed. Lynkuet (elinzanetant) US prescribing information, current major warning revision August 2026. https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-lynkuet · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f42884ff-7dff-419c-8a0c-affe2ed73818

¹² US Food and Drug Administration. “Menopause.” Current consumer and regulatory guidance on FDA-approved and compounded hormone therapy. https://www.fda.gov/consumers/womens-health-topics/menopause

¹³ US Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

¹⁴ US Drug Enforcement Administration. “Drug Scheduling.” Testosterone is listed as a Schedule III controlled substance. https://www.dea.gov/drug-information/drug-scheduling

¹⁵ The HRT Index. “Find My HRT Path.” Current live tool disclosure and routing description, verified August 2026. https://thehrtindex.com/find-my-hrt-path/

¹⁶ US Department of Health and Human Services. “Individuals’ Right under HIPAA to Access their Health Information.” https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/access/index.html

¹⁷ DailyMed. Avastin (bevacizumab) US prescribing information. The label warns that Avastin increases arterial and venous thromboembolic events. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e

¹⁸ Faculty of Sexual & Reproductive Healthcare. Contraception for Women Aged Over 40 Years, amended September 2024. https://fsrh.org/Common/Uploaded%20files/documents/fsrh-guideline-contraception-for-women-aged-over-40-years.pdf

¹⁹ Halldorsdottir S, Dahlstrand H, Stålberg K. “Gynecologists are afraid of prescribing hormone replacement to endometrial/ovarian cancer survivors despite national guidelines—a survey in Sweden.” Upsala Journal of Medical Sciences. 2018;123(4):225–229. https://doi.org/10.1080/03009734.2018.1544597

²⁰ The North American Menopause Society. “The 2023 nonhormone therapy position statement.” Menopause. 2023;30(6):573–590. https://doi.org/10.1097/GME.0000000000002200

²¹ Donohoe F, O’Meara Y, Roberts A, et al. “Multimodal, technology-assisted intervention for the management of menopause after cancer improves cancer-related quality of life.” Cancers. 2024;16(6):1127. https://doi.org/10.3390/cancers16061127

²² US Food and Drug Administration. “Testosterone Information.” https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information